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Abstract
Background:  Parkinson's disease (PD) is a neurodegenerative disorder. The diagnosis of
Parkinsonism is challenging because currently none of the clinical tests have been proven to help in
diagnosis. PD may produce characteristic perturbations in the metabolome and such variations can
be used as the marker for detection of disease. To test this hypothesis, we used proton NMR and
multivariate analysis followed by neural network pattern detection.
Methods & Results: 1H nuclear magnetic resonance spectroscopy analysis was carried out on
plasma samples of 37 healthy controls and 43 drug-naive patients with PD. Focus on 22 targeted
metabolites, 17 were decreased and 5 were elevated in PD patients (p < 0.05). Partial least squares
discriminant analysis (PLS-DA) showed that pyruvate is the key metabolite, which contributes to
the separation of PD from control samples. Furthermore, gene expression analysis shows
significant (p < 0.05) change in expression of PDHB and NPFF genes leading to increased pyruvate
concentration in blood plasma. Moreover, the implementation of 1H- NMR spectral pattern in
neural network algorithm shows 97.14% accuracy in the detection of disease progression.
Conclusion: The results increase the prospect of a robust molecular definition in detection of PD
through the early symptomatic phase of the disease. This is an ultimate opening for therapeutic
intervention. If validated in a genuinely prospective fashion in larger samples, the biomarker
trajectories described here will go a long way to facilitate the development of useful therapies.
Moreover, implementation of neural network will be a breakthrough in clinical screening and rapid
detection of PD.
Background
Parkinson's disease (PD) is a slow, progressive degenera-
tive disorder of the central nervous system [1]. It is charac-
terized by muscle rigidity, tremor, slowing of physical
movement (Bradykinesia) and, in extreme cases, loss of
physical movement (Akinesia) [2]. The classification of
the stages were done based on Unified Parkinson's Dis-
ease Rating Scale (UPDRS) [3] or on an equivalent rating
scale value such as Hoehn and Yahr scale and Schwab and
England Activities of Daily Living Scale. The UPDRS has
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been used extensively by researchers and clinicians
around the world. The rating scale is categorized as stages
based on bradykinesia, dyskinesias, rigidity, posture,
swinging arms, walking, tremor, gesture, seborrhea,
speech, sensory complaints, depression, postural stability,
insomnia, leg agility and independence. The diagnosis is
based on medical history and neurological examinations
[4]. The current diagnosis of PD remains unclear, because
of the complex spectrum of symptoms and their similari-
ties with other neurodegenerative diseases, such as multi-
ple system atrophy and progressive supranuclear palsy.
Moreover, clinical diagnosis fails to identify PD before
they cause a significant loss of dopamine neurons [5].
There is immense need for early detection [6] and more
effective drugs for the cure of PD. An understanding of the
molecular characteristics underlying the disease processes
of PD is a prerequisite for the development of biomarker
in the early detection for providing high value therapeu-
tics.
Biomarkers serve as tools for diagnosis of any disease usu-
ally performed on readily accessible body fluids, such as
cerebrospinal fluid (CSF), serum, urine or saliva. Meta-
bolic profiling is one of the most important techniques,
greatly focused for the detection of biomarkers for diagno-
sis of diseases [7,8]. Several encouraging results were
obtained using metabolite profiling in an attempt to diag-
nose coronary heart disease [9], diabetes mellitus [10],
eclampsia [11], lipid disorder [12], colon carcinoma [13],
epithelial ovarian cancer [14], hypertension [15], kidney
deficiency syndrome [16], motor neuron disease [17] and
liver cancer [18]. Several techniques are presently availa-
ble for metabolite profiling, such as nuclear magnetic res-
onance spectroscopy (NMR), mass spectrometry (MS),
high-performance liquid chromatography (HPLC), gas
chromatography (GC) and optical spectroscopic (OS)
analysis. NMR spectroscopy technique is more ease for
rapid metabolite detection because it requires an uncom-
plicated, preprocessing procedure, and it is a feasible
method to obtain essential information from complex
and intact biological samples. Recent studies show that
NMR metabolic profiling plays a vital role in clinical diag-
nosis [19,20].
In the present study, 1H (proton) NMR spectroscopy was
executed to examine the plasma samples of 37 normal
and 43 drug-naive patients of PD to identify the metabo-
lite variations of 22 targeted metabolites between the
blood plasma of healthy individuals and patients.
Materials and methods
Clinical sample
Clinical samples were collected from the out-patient set-
ting of the Department of Neurology at SRM Hospital,
Tamil Nadu, India. Drug-naive samples of 43 PD patients
were collected and 37 samples of age and gender-matched
healthy controls were included for comparative study
(Table 1), written consent was obtained from each partic-
ipant during in-person interview and blood donation.
Data on gender, age and weight were collected. For partic-
ipants with PD, date of the symptom onset, date of diag-
nosis, and family history of PD were recorded. The ethical
committee of SRM Medical College Hospital & Research,
India reviewed and approved the protocol of this study
(Ref. No.3496/Dean/07). The pathological status was well
studied by neurological specialists of hospital and the dis-
ease stages were classified by UPDRS.
Preparation of samples
Blood samples (4 ml) were collected in EDTA vacutainer
tube (Becton Dickinson, Franklin Lakes, NJ) from individ-
uals and immediately centrifuged for 5 min at 14,000 rpm
using eppendorf centrifuge to separate plasma from other
cellular material. Subsequently, the plasma was trans-
ferred to fresh eppendorf tube and kept at -20°C before
processing. 500 μl of plasma was processed by Nanosep
3KD (Pall Co., New York, USA) micro centrifuge tube to
extract the metabolites from the sample and to avoid pro-
tein interference in the extract. The obtained metabolite
extracts were dissolved in D2O (Merck KGaA, Darmstadt,
Table 1: Statistics
Sample Information Number of samples Statistics Gender
Mean Age SD Male Female
Normal 37 58.486 11.843 21 16
PD-Stage 1 15 58.2 11.651 9 6
PD-Stage 2 13 60.153 11.238 8 5
PD-Stage 3 15 55.66 12.056 8 7
Statistics of research participant's involved in the study.Journal of Biomedical Science 2009, 16:63 http://www.jbiomedsci.com/content/16/1/63
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Germany) and 500 μM of 2,2-dimethyl-2-silapentane-5-
sulfonate (DSS) (Sigma Chemical Co., St. Louis, MO,
U.S.A) were added as an internal standard in preparation
for 1H-NMR analysis.
Proton NMR spectrum
All experimental samples were subjected to 1H-NMR spec-
trum. The spectrum was acquired using the Bruker AV-III-
500 MHz (Bruker Biospin, Inc., Milton, Canada) operat-
ing at 500.1323506 MHz and equipped with a five mm
PABBO BB probe at 295K. A total of 231 scans was col-
lected over a sweep width of 6066 Hz, with a 5s repetition
time. Fourier transformation, phasing, line broadening
and baseline correction was made prior to the analysis of
metabolites. Chemical shift assignments were conformed
by performing correlation spectroscopy (COSY) and total
correlation spectroscopy (TOCSY) 2D NMR using stand-
ard Bruker pulse programs.
Metabolite determination
To evaluate the metabolites variability between biofluid
derived from patients and healthy controls, proton NMR
spectra was analyzed using the novel Chenomx NMR 5.1
software (Chenomx. Inc., Edmonton, Canada). The Pro-
filer module was used for the determination and quantifi-
cation of 22 metabolites in the plasma by comparing with
a library of 292 metabolites of 1H-NMR spectra of each
standard compound recorded at 500 MHz. The calibra-
tion of chemical shift was made by DSS internal standard
(0.0 ppm) resonance.
Statistical analysis
The profiled data were imported into GeneSpring GX7.3
microarray software (Agilent Technologies Inc., Santa
Clara, California), in which analysis of variance (ANOVA)
was performed. In order to confirm the biomarkers differ-
entiating the patients with PD from matched controls,
partial least square discriminant analysis (PLS-DA) was
employed using Umatrices software (Umetrics, Inc., Kin-
nelon, NJ).
Systems biological approach
Pubgene index [21] was used to identify the interacting
genes with pyruvate dehydrogenase complex. Moreover,
pyruvate dehydrogenase is multi enzyme complex, which
includes PDHB, PDHA1, PDHA2, DLAT, DLD and PDHX
[22].
Gene expression analysis
Secondary microarray data analysis was performed in the
cellular blood of PD patients on previously published
data retrieved from gene expression omnibus [GEO:
GDS2519], NCBI database. The analysis was performed
on 72 samples, which include 22 normal and 50 early PD
samples [23]. Prior to analysis, the basic processing of raw
data was carried out on 40 gene spots identified from the
gene interactions, such as PDHB, PDHA1, PDHA2, DLAT,
DLD, PDHX, CAT, CD4, CD8A, CS, DUOX1, DUOX2,
EDC4, FAM48A, FGF13, FGF, GCG, G6PD, GSR, HSPD1,
IFNG, INS, INSR, JUN, NEUROG3, NOS1, NOS2A,
NOS3, NPFF, OGDH, PDX1, PTPRC, SST, SYT1, THEG,
TMEM16A, TNF, TTF2, UNC5C and WNK1. The analysis
was made only on these selected genes using GeneSpring
GX7.3 microarray software.
Artificial neural network (ANN) for diagnosis
The neural-network design consisted of a three-layer net-
work: an input layer, with 13 units containing the infor-
mation on the diagnostic criteria; a hidden layer, with 7
units; and an output layer for the detection of PD based
on stages. A NeuNet Pro software (CorMac Technologies
Inc., Canada), back prop algorithm were used for the pre-
diction of disease stages. Back prop algorithm of NeuNet
Pro software accepts the clinical data as numerical inputs.
The training variables include age, gender, amplitude (si)
of 10 NMR peaks (1.32 ppm, 1.46 ppm, 2.55 ppm, 2.60
ppm, 2.70 ppm, 3.10 ppm, 3.22 ppm, 3.54 ppm, 3.86
ppm, 4.02 ppm) representing ~292 metabolites and,
together with information about disease status, normal
(coded 0), stage1 (coded 1), stage2 (coded 2), stage3
(coded 3). The patterns of input facts associated with diag-
noses were trained with randomly selected 45 individuals
from the set 80 with known pathological status which
includes 17 normal and 28 PD patients (9 samples of
stage 1, 8 samples of stage 2 and 11 samples of stage 3).
The training process continued until the differences
between the network classifications and the clinical diag-
noses became acceptable. Once the network was trained,
the remaining 35 individuals were "tested," by means of
the trained network. The neural network classifications
were then compared with the known clinical diagnoses, to
see whether the network was able to classify disease status
reliability.
Results
Investigation of plasma samples for the detection of
metabolite variations were performed by comparing the
normal with PD patients by proton NMR. The typical
analysis of NMR spectra aimed for 22 metabolites hypo-
thetically suggests a critical role in PD.
Metabolite variations
The mean concentrations of galactitol, glycerol, methyl-
amine, trimethylamine, ethanolamine, suberate, glutar-
ate, malate, methylmalonate, succinate, acetate,
gluconate, threonate, glucolate, ascorbate, isocitrate, and
citrate were significantly decreased, while the levels of
ethymalonate, pyruvate, myoinositol, sorbitol and pro-
pylene glycol was elevated in the patient samples. The
average difference in concentrations of metabolitesJournal of Biomedical Science 2009, 16:63 http://www.jbiomedsci.com/content/16/1/63
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between normal and patients was showed in heat map
(Fig. 1).
Statistical analysis
Analysis of variance (ANOVA) was performed to demon-
strate a significant difference between PD patients and
controls. The results showed the significance at p < 0.05
(Table 2). To explore the metabolite multidimensional
data, unsupervised statistical methods were executed on
samples. PLS-DA plots' scores based on 1H-NMR spectra
of plasma samples showed a clear differentiation between
healthy volunteers and drug-naive patients (Fig 2). The
loading coefficient map indicates that myoinositol, gluci-
tol, citrate, acetate, succinate and pyruvate were predomi-
nantly responsible for the separation between classes (Fig
3). Hence, the results from 1H-NMR spectroscopy showed
significantly elevated concentrations of myoinositol, glu-
citol and pyruvate in plasma samples of drug-naive
patients, confirming the likely importance of these mole-
cules as biomarker.
Genetic aspects of pyruvate variation
To determine the genetic basis of pyruvate variation, the
systems biological approach was performed using PUB-
GENE index on DLAT, DLD, PDHX, PDHB, PDHA1 and
PDHA2 genes. The result explores the interaction of 46
genes, such as AKR1CL2, CAT, CD4, CD8A, CS, DMRT3,
DUOX1, DUOX2, EDC4, FAM48A, FGF13, FGF2,
FLJ21936, GCG, GCSL, G6PD, GSR, HSPD1, IFNG, INS,
INSR, JUN, NEUROG3, NOS1, NOS2A, NOS3, NPFF,
OGDH, PDX1, PTPRC, SST, SYT1, THEG, TMEM16A,
TNF, TTF2, UNC5A, UNC5B, UNC5C and WNK1 includ-
ing pyruvate dehydrogenase components (Fig. 4). The
biological significance of these genes in PD was further
validated by secondary gene expression analysis. The
expression analysis was executed only on 40 gene spots by
excluding 6 genes such as GCSL,  FLJ21936, DMRT3,
Heat map differentiation of metabolite Figure 1
Heat map differentiation of metabolite. Average metabolite variability of blood plasma between PD patients (n = 43) and 
healthy controls (n = 37) are shown. Cluster analyses of the 22 differentially altered metabolites are selected based on signifi-
cance P value (P < 0.05). The heat map depicts high (red) and low (green) relative levels of metabolite variation.Journal of Biomedical Science 2009, 16:63 http://www.jbiomedsci.com/content/16/1/63
Page 5 of 12
(page number not for citation purposes)
AKR1CL2, UNC5A and  UNC5B. The result shows the
moderate down regulation of CAT, PDHB, NPFF,
TMEM16A, UNC5C, FGF13, JUN and up regulation of
INSR, THEG, NOS1, FAM48A, PTPRC, OGDH, SYT1,
FGF2 and SST genes in cellular blood of PD. In addition,
statistical analysis was carried out on 16 genes showed the
significance of pyruvate dehydrogenase lipoamide beta
(PDHB) and neuropeptide FF-amide peptide precursor
(NPFF) genes with p < 0.05.
Neural network classification
The neural network training was performed as described
above, on the basis of diagnostic criteria for the 45 indi-
viduals of known variable information. The network,
tested with 35 individuals, the success rate in classification
of the test set was 97.14% (34/35) accuracy, the sensitivity
was 93.33% (14/15, one case of stage 1 was misdiagnosed
as stage 2 PD), the specificity was 100% (20/20) (Fig. 5).
Moreover, the values generated by the neural network
were ranged from 0 to 3. On the basis of these values, indi-
viduals were assigned as affected or normal group. Indi-
viduals whose final predicted values were ≤ 0.2 were
assigned to the normal group, and those whose output
values ≥ 0.2 were assigned to the PD. For instance the pre-
dicted range from < 0.2 > 1.03 assigned as stage 1, ≤ 1.03
> 2.06 as stage 2 and the values ≤ 2.06 ≥ 3 as stage 3 (Table
3).
Discussion
The present study is focused to identify the metabolic
marker for the detection of PD from plasma and to vali-
date the variations by spotting out through gene responsi-
bility.
Several studies have been indicated the gene variation in
PD [24-28] which may lead to metabolic abnormalities
that are detectable in peripheral tissues. Few successful
break through have shown metabolite variations in CSF
and serum samples of PD. For instance, glutamate was
found to be decreased in parkinsonian CSF compared to
control subjects, a result reported in earliest analyses of
parkinsonian CSF [29-31]. Subsequent study shows that
the increased level of glycine, aspartate and glutamate in
the plasma of parkinsonian patients [32]. Increase in CSF
glycine also been observed in PD [33]. Previous study of
PD patients showed reduction in concentrations of
arginine and methionine in serum, while the level of
valine was increased [34]. Additionally, a significant
decrease in CSF isoleucine, alanine, lysine and moderate
increase of a glutamine level was very well observed in PD
[34]. Recent study shows the feasibility of potential diag-
nosis of PD from the detection of increased 8-OHdG in
serum and urine of PD [35]. Furthermore, several reports
indicate that there is a reduction of complex 1 activity in
the electron transport chain of PD [36-41]. From the
detailed knowledge of these studies, 22 metabolites,
which play a role in mitochondrial function and other
related pathway, have been targeted.
Analysis of the 1H NMR spectra of plasma samples
showed differential distribution of these metabolites in
drug-naive patients compared to the healthy volunteers.
Table 2: Statistical significance of metabolites
S. No Metabolites Significance (P < 0.05)
1 Glucitol 0.031
2 Galactitol 0.0420
3 Glycerol 0.0321
4 Methylamine .0276
5 Trimethylamine 0.0318
6 Ethanolamine 0.0478
7 Suberate 0.0211
8G l u t a r a t e 0 . 0 2 1 0
9 Malate 0.133
10 Methylmalonate 0.0398
11 Succinate 0.0291
12 Acetate 0.0201
13 Gluconate .0365
14 Threonate 0.0195
15 Glucolate .0371
16 Ascorbate 0.0489
17 Isocitrate 0.0263
18 Pyruvate 0.0107
19 Citrate 0.0209
20 Ethylmalonate 0.0481
21 Myoinositol 0.0199
22 Propylene glycol 0.0429
Analysis of variance (ANOVA) of 22 metabolites showing the clear 
significant difference between PD patients and controls with p < 0.05Journal of Biomedical Science 2009, 16:63 http://www.jbiomedsci.com/content/16/1/63
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The targeted metabolite profiling of 22 compounds in
blood plasma was characteristically altered in patients
with PD, and most of these metabolites have decreased in
concentration. The results showed that, this approach has
great hope in diagnosis of PD. Moreover, this study was
made with unmedicated PD patients to controls, to avoid
the confounding effects of any medications. The key
metabolites, such as myoinositol, sorbitol, citrate, acetate,
succinate and pyruvate are significant in contribution for
the separation between metabolite profiles of unmedi-
cated PD patients and controls.
Plasma myoinositol level was significantly increased in
the drug-naive patients. Elevation of myoinositol concen-
trations implies the decrease in activity of sciatic motor-
nerve conduction velocity determined in animal models
[42,43]. Elevated plasma myoinositol has not previously
been reported for PD. However, studies show the abnor-
mal myoinositol levels in the brain of neurologically dis-
eased patients and other disorders [44-47]. Raised
myoinositol levels in the basal ganglia were recently
observed in PD patients under exercise condition detected
using magnetic resonance spectroscopy [48]. Addition-
ally, plasma sorbitol level was significantly increased in
drug-naive patients. Sorbitol has been linked to drug treat-
ment in PD [49], yet our observation of an elevation of
plasma sorbitol concentrations in drug-naive patients
may be due to impairment in oxidative stress [50,51]. The
elevated levels of sorbitol have been reported in the CSF
of mood disorder patients, which relates to oxidative
stress [52]. Surprisingly, elevation in the plasma sorbitol
level has not been reported in PD to our knowledge.
Together with the significant findings of myoinositol and
sorbitol in plasma imply the dysfunction of polyols met-
abolic pathway. Polyols pathway is a minor metabolic
pathway of glucose running parallel to glycolysis, whose
activity is altered in mitochondrial dysfunction [53].
However, malfunctioning of mitochondria is previously
Partial least square discriminant analysis Figure 2
Partial least square discriminant analysis. PLS-DA scores plot showing a significant separation between control subjects 
(n = 37) and unmedicated PD patients (n = 43) using complete digital maps. The observations coded according to class mem-
bership: black square = controls; red square = PD patients.Journal of Biomedical Science 2009, 16:63 http://www.jbiomedsci.com/content/16/1/63
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reported in PD [36-41], and it is the pedestal of this study.
Detection of glucose concentration were not been carried
out but abnormality of glucose metabolism was previ-
ously reported in PD patients [54].
More interestingly citrate, malate, acetate, succinate and
pyruvate are significantly varied in PD plasma samples,
contributes to the major distinction of PD from normal
samples in PLS-DA analysis. These metabolites, such as
citrate, acetate, succinate and malate were decreased,
while increase in pyruvate concentration was noticed.
Pyruvate is the end metabolite of glycolysis. It enters
Kreb's cycle as acetyl-coA by the catalysis of enzyme pyru-
vate dehydrogenase in the presence of the coenzyme
NAD+. The accumulation of pyruvate or its increased con-
centration in plasma may be due to abnormal activity of
pyruvate dehydrogenase complex and its interacting genes
in patients. Increased pyruvate CSF has already been
reported in Alzheimer's patients [55,56]. The other inter-
mediates of Kreb's cycle such as citrate, malate and succi-
nate were considerably decreased in this study, which may
correlate to alteration of pyruvate dehydrogenase activity.
Moreover, the detection of other metabolites of Kreb's
cycle was not executed in our analysis. Systems biological
approach was carried out on pyruvate dehydrogenase
components to identify its interacting genes which are
hypothesized as the cause for the increased plasma pyru-
vate concentration. The analysis reveals 46 interacting
genes together with pyruvate dehydrogenase components.
The significant variation in plasma pyruvate was validated
by gene expression analysis of 46 genes derived from sys-
tems biological approach. The expression analysis was
executed only on 40 genes and the other 6 genes in which
the following FLJ21936, DMRT3, AKR1CL2, UNC5A and
UNC5B were excluded from this study, because these
genes are not expressed in blood cells and GCSL gene was
also eliminated since it is considered as an alias of DLD
gene. The analysis of 40 genes shows differential regula-
tion of 16 genes in comparison to control. Interestingly,
out of 16 genes, 9 genes have been previously reported in
PD, such as CAT, FGF13, JUN, INSR, NOS1, OGDH, SYT1,
FGF2 and SST [57-65]. Furthermore, statistical analysis of
these genes show the significance of NPFF and PDHB with
Biomarker detection Figure 3
Biomarker detection. The loading coefficient map showing that myoinositol, glucitol, citrate, acetate, succinate and pyruvate 
were predominantly responsible for the classification of groups.Journal of Biomedical Science 2009, 16:63 http://www.jbiomedsci.com/content/16/1/63
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p < 0.05. NPFF gene plays a major role in inflammation
modulation, neuroendocrine function and cardiovascular
regulations [66], where as, PDHB gene is the beta subunit
of pyruvate dehydrogenase, directly associated with pyru-
vate dehydrogenase activity and mitochondrial dysfunc-
tion. Abnormal activity of pyruvate dehydrogenase is the
basis of our study in representing the variation in pyruvate
concentration. The impairment of cardiovascular regula-
tion [67], inflammation [68] and neuroendocrine func-
tion [69] were reported in PD and this may suggest the
influence of differential regulation of NPFF gene. The bio-
logical significance of these genes related to PD has not
been reported previously. Hence, the variation in pyruvate
concentration can be considered as a marker for detection
of PD and future studies need to be carried out on the fac-
tors and the hidden mechanism involved in variations of
NPFF and PDHB in PD.
Prior study indicates no correlation between metabolite
variation with severity and duration in PD [24]. To bring
out the correlation, NMR peak amplitude representing the
~290 metabolite was included as one of the variables in
the prediction of disease stages by neural network. The
ANN was trained with variable parameters as described
above. More fascinating results emerged from neural net-
work and it is capable to predict early stages of PD, with a
good accuracy using these variables. The optimized net-
work yield has an accuracy of 97.14% in detecting PD
patients. Based on the present study it has been confirmed
that the association between disease progression and
metabolite variation is strong and it is more accurate than
the current diagnosis [23] of PD.
Conclusion
The present study concludes that the application of NMR
metabolite profiling of plasma fluid can provide an effi-
cient means for detection of Parkinson's disease. We iden-
Pyruvate dehydrogenase component interacting genes Figure 4
Pyruvate dehydrogenase component interacting genes. The systems biological approach showing the complex interac-
tion of pyruvate dehydrogenase components (red) with 40 genes.Journal of Biomedical Science 2009, 16:63 http://www.jbiomedsci.com/content/16/1/63
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Table 3: Neural network prediction
Sample ID ANN classification values Neural network designation Clinical designation
2 -0.085 Normal Normal
3 -0.065 Normal Normal
4 -0.045 Normal Normal
6 -0.04 Normal Normal
7 -0.02 Normal Normal
8 -0.01 Normal Normal
10 -0.01 Normal Normal
11 0 Normal Normal
12 0.02 Normal Normal
13 0.03 Normal Normal
14 0.052 Normal Normal
15 0.059 Normal Normal
20 0.073 Normal Normal
21 0.078 Normal Normal
22 0.092 Normal Normal
29 0.105 Normal Normal
31 0.112 Normal Normal
32 0.118 Normal Normal
34 0.122 Normal Normal
35 0.1255 Normal Normal
18 0.97 PD-Stage 1 PD-Stage 1
23 0.97 PD-Stage 1 PD-Stage 1
24 0.98 PD-Stage 1 PD-Stage 1
26 0.99 PD-Stage 1 PD-Stage 1
1 1.01 PD-Stage 1 PD-Stage 1
27 1.531 PD-Stage 2 PD-Stage 1*
5 1.62 PD-Stage 2 PD-Stage 2Journal of Biomedical Science 2009, 16:63 http://www.jbiomedsci.com/content/16/1/63
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17 1.73 PD-Stage 2 PD-Stage 2
25 1.97 PD-Stage 2 PD-Stage 2
28 1.97 PD-Stage 2 PD-Stage 2
30 1.99 PD-Stage 2 PD-Stage 2
9 2.46 PD-Stage 3 PD-Stage 3
16 2.56 PD-Stage 3 PD-Stage 3
19 2.82 PD-Stage 3 PD-Stage 3
33 2.96 PD-Stage 3 PD-Stage 3
*Sample ID: Misclassified stage 1 as stage 2 by ANN
Neural network classification values, neural network designation and disease designation, for 35 Individuals who have known clinical information. 
Individuals denoted by a (*) indicates the misclassification of PD stage1 as stage2 by ANN.
Table 3: Neural network prediction (Continued)
Distribution of patients and healthy individuals Figure 5
Distribution of patients and healthy individuals. Neural network classification of disease for 35 individuals (x-axis) with 
known clinical information. Values (y-axis) are predicted value over the trained network and are 0 to3; values ≥ 0.2 reflect a 
neural-network classification of "normal," and values ≤ 0.2 reflect a neural-network classification of "PD". Individuals denoted 
by a Violet rhombus are normal, red arrow are clinically stage 1 PD, blackened circle are stage 2, blackened square are stage 3 
PD respectively.Journal of Biomedical Science 2009, 16:63 http://www.jbiomedsci.com/content/16/1/63
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tified abnormalities in 22 circulating metabolites, which
bring out the scope for the diagnosis of PD. Moreover, the
result obtained from neural network approach is more
feasible for the stage wise detection. However, the accu-
racy of neural network is questionable unless the study
focused with the larger samples.
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